Truist Financial analyst Les Sulewski maintained a Buy rating on Teva Pharmaceutical today and set a price target of $45.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Les Sulewski has given his Buy rating due to a combination of factors tied to Teva’s solid execution and strengthening growth profile. The company’s first-quarter performance reinforced confidence in management’s ability to deliver on its strategic pivot toward innovative medicines, prompting him to raise his price target to $45 as the outlook for earnings and pipeline value improves.
He also views the Emalex acquisition as a highly attractive catalyst, adding a late-stage Tourette syndrome asset with potential peak sales approaching $1 billion and meaningful U.S. market exclusivity. In his view, ecopipam’s differentiated mechanism, favorable Phase 3 data, and ability to address a major unmet need position Teva for significant upside in neurology, while the broader pipeline, including its anti–IL‑15 program, offers additional optionality and justifies a continued bullish stance.
In another report released on April 23, Piper Sandler also maintained a Buy rating on the stock with a $41.00 price target.